[Influence of sodium alginate on the intestinal transit in low birth weight newborn infants].

Pediatrie Pub Date : 1993-01-01
J P Chouraqui, I Morer, P Renard, M C Bielsky, C Richard-Berthe, P Rambaud
{"title":"[Influence of sodium alginate on the intestinal transit in low birth weight newborn infants].","authors":"J P Chouraqui,&nbsp;I Morer,&nbsp;P Renard,&nbsp;M C Bielsky,&nbsp;C Richard-Berthe,&nbsp;P Rambaud","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Sodium alginate (Gaviscon) is used in the management of gastro-oesophageal reflux in infants. No digestive disadvantages have as yet been reported with the use of the Gaviscon formula available in France, which contains neither aluminium hydroxide nor thickener. Twenty-two healthy neonates were prospectively studied before and after Gaviscon treatment in order to characterize their whole gut transit time with the use of a carmine index. The head of the marker appeared within the same time in both experiments but the appearance of the tail was earlier in the treated infants (P < 0.05), without any subsequent clinical consequences. The slight increase shown in the rate of the clearance of the marker from the gut, is likely to be related to a less proximal to distal dispersion of the marker, subsequently to physical changes occurring in the viscous alginate. Frequency and consistency of the stools were unmodified by treatment and accordingly Gaviscon can be regarded as having no deleterious effect on transit time in neonates.</p>","PeriodicalId":19935,"journal":{"name":"Pediatrie","volume":"48 6","pages":"473-7"},"PeriodicalIF":0.0000,"publicationDate":"1993-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatrie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Sodium alginate (Gaviscon) is used in the management of gastro-oesophageal reflux in infants. No digestive disadvantages have as yet been reported with the use of the Gaviscon formula available in France, which contains neither aluminium hydroxide nor thickener. Twenty-two healthy neonates were prospectively studied before and after Gaviscon treatment in order to characterize their whole gut transit time with the use of a carmine index. The head of the marker appeared within the same time in both experiments but the appearance of the tail was earlier in the treated infants (P < 0.05), without any subsequent clinical consequences. The slight increase shown in the rate of the clearance of the marker from the gut, is likely to be related to a less proximal to distal dispersion of the marker, subsequently to physical changes occurring in the viscous alginate. Frequency and consistency of the stools were unmodified by treatment and accordingly Gaviscon can be regarded as having no deleterious effect on transit time in neonates.

海藻酸钠对低出生体重新生儿肠道运输的影响
海藻酸钠(加夫iscon)用于治疗婴儿胃食管反流。在法国使用既不含氢氧化铝也不含增稠剂的加夫斯康配方,迄今还没有报道有消化方面的缺点。对22名健康新生儿进行了前瞻性研究,在Gaviscon治疗前后使用胭脂红指数来表征他们的整个肠道运输时间。在两个实验中,标记头在同一时间出现,但尾的出现在治疗婴儿中更早(P < 0.05),没有任何后续的临床后果。标记物从肠道清除率的轻微增加,可能与标记物从近端到远端分散较少有关,随后与粘性藻酸盐发生的物理变化有关。治疗未改变大便的频率和稠度,因此可以认为Gaviscon对新生儿的转运时间没有有害影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信